Skip to main contentAI and Advanced
/
CAPLIPOINT · NSEMarket ticker unavailable · configure an authorised index feed
CA
NSE · Equity shares · Biotechnology & Drugs-1.00 · -0.04%
Caplin Point Laboratories CAPLIPOINT
NSE:INR 2,571
BSE:INR 2,584.55
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for CAPLIPOINT
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,572
Day rangeINR 2,490.5 — INR 2,606.7
52-week rangeINR 1,500.3 — INR 2,877.3
Volume2.12 L
Market cap19,686.24
P/E17.84
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,187.19
Net Income (INR Cr)641.24
Rev Growth (5 Year %)15.56
EPS Growth (5 Year %)21.52
P/E Ratio17.84
Book Value464.74
EPS84.11
Price/BV5.53Computed
Research path: Interpret Caplin Point Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
CAPLIPOINTCaplin Point Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 4,045.48 | 3,207.85 | 2,698.12 |
| Cash Equivalents | 621.04 | 59 | 49.03 |
| Other Liabilities Total | 14.08 | 12.56 | 19.09 |
| Accrued Expenses | 20.02 | 34.55 | 25.3 |
| Common Stock Total | 15.2 | 15.2 | 15.19 |
| Other Current Assets Total | 250.07 | 8.82 | 10.57 |
| Total Assets | 4,045.48 | 3,207.85 | 2,698.12 |
| Current Portof LT Debt/Capital Leases | 2.55 | 2.11 | 1.05 |
| Total Equity | 3,586.42 | 2,850.49 | 2,315.71 |
| Long Term Investments | 501.71 | 286.29 | 137.64 |
| Retained Earnings(Accumulated Deficit) | 3,496.64 | 2,475.53 | 1,977.21 |
| Total Common Shares Outstanding | 7.6 | 7.6 | 7.59 |
| Tangible Book Valueper Share Common Eq | 464.74 | 372.96 | 303.28 |
| Total Liabilities | 459.06 | 357.36 | 382.41 |
| Total Debt | 4.61 | 5.02 | 1.97 |
| Short Term Investments | 459.88 | 700.79 | 642.15 |
| Cashand Short Term Investments | 1,080.92 | 894.53 | 780.7 |
| Total Receivables Net | 825.81 | 880.9 | 736.81 |
| Deferred Income Tax | 12.6 | Not available | Not available |
| Accounts Receivable-Trade Net | 825.81 | 669.32 | 562.36 |
| Property/Plant/Equipment Total-Net | 759.76 | 673.73 | 556.76 |
| Minority Interest | 44.38 | 35.9 | 31.12 |
| Total Current Liabilities | 385.94 | 305.99 | 331.28 |
| Total Inventory | 428.86 | 336.1 | 363.04 |
| Accounts Payable | 296.03 | 217.58 | 209.41 |
| Other Currentliabilities Total | 67.34 | 51.75 | 95.52 |
| Total Long Term Debt | 2.06 | 2.91 | 0.92 |
| Intangibles Net | 53.83 | 7.05 | 9.75 |
| Other Long Term Assets Total | 133.22 | 77.75 | 80.08 |
| Note Receivable-Long Term | 11.3 | 20.58 | 18.2 |
| Unrealized Gain(Loss) | 74.58 | 74.58 | 74.58 |
| Total Current Assets | 2,585.66 | 2,133.95 | 1,892.92 |
| Capital Lease Obligations | 2.06 | 2.91 | 0.92 |
| Accumulated Depreciation Total | Not available | -300.73 | -239.57 |
| Other Equity Total | Not available | 246.17 | 219.1 |
| Prepaid Expenses | Not available | 13.6 | 1.8 |
| Additional Paid-In Capital | Not available | 19.36 | 15.41 |
| Cash | Not available | 134.74 | 89.52 |
| Property/Plant/Equipment Total-Gross | Not available | 835.24 | 679.71 |
| Goodwill Net | Not available | 8.5 | 2.77 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| ESOP Debt Guarantee | Not available | 19.65 | 14.22 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.54
Price to Sale Ratio9.00
Growth
Debt 5Yr CAGR %-24.17
Margins
Operating Margin 12m31.46
Operating Margin 5y Avg29.42
Net Profit Margin 12m29.71
Net Profit Margin 5y27.33
Yield
Dividend Yield %0.16
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk34.09
Analyst consensus
ConsensusStrong Buy
Consensus score1.50
Analyst opinions2
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 70.57%
- FII
- 5.76%
- MF
- 2.03%
- Other
- 21.64%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Enterprise value to revenue forward of Caplin Point Laboratories Limited – NSE:CAPLIPOINT - TradingViewMarket news · 20 Jul 2026, 4:28 pm
Enterprise value to revenue forward of Caplin Point Laboratories Limited – NSE:CAPLIPOINT TradingView
Caplin Point Laboratories Ltd Upgraded to Buy on Strong Technical and Financial Performance - MarketsMojoMarket news · 15 Jul 2026, 8:44 am
Caplin Point Laboratories Ltd Upgraded to Buy on Strong Technical and Financial Performance MarketsMojo
Caplin Point Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook - MarketsMojoMarket news · 15 Jul 2026, 8:03 am
Caplin Point Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook MarketsMojo
Trade Spotlight: How should you trade Sun Pharma, Balrampur Chini Mills, Blue Star, Caplin Point Labs,... - Moneycontrol.comMarket news · 15 Jul 2026, 6:52 am
Trade Spotlight: How should you trade Sun Pharma, Balrampur Chini Mills, Blue Star, Caplin Point Labs,... Moneycontrol.com
Caplin Point Laboratories Shares Trade in Narrow Range - WhalesbookMarket news · 15 Jul 2026, 6:42 am
Caplin Point Laboratories Shares Trade in Narrow Range Whalesbook
Stock to buy today: Caplin Point Laboratories (₹2,658) – BUY - BusinessLineMarket news · 15 Jul 2026, 6:30 am
Stock to buy today: Caplin Point Laboratories (₹2,658) – BUY BusinessLine
Corporate actions
Events
- board MeetingsQuarterly Results & Final Dividend
- dividendRs.4.0000 per share(200%)Interim Dividend
- board MeetingsAudited Results & Interim Dividend
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Caplin Point Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- CAPLIPOINT
- BSE Code
- 524742
Questions
Stock FAQ
What is the symbol and ISIN of Caplin Point Laboratories?
Caplin Point Laboratories has the symbol CAPLIPOINT and ISIN - INE475E01026.
What is the current price of Caplin Point Laboratories?
Caplin Point Laboratories is currently trading at INR 2,571.00.
What are the year high and year low of Caplin Point Laboratories?
Caplin Point Laboratories has a year high of INR 2,877.30 and a year low of INR 1,500.30.
What is the market capitalization of Caplin Point Laboratories?
Caplin Point Laboratories has a market capitalization of INR 19,686.24 crore.
What is the P/E ratio of Caplin Point Laboratories?
Caplin Point Laboratories has a P/E ratio of 17.84.
What is the dividend yield of Caplin Point Laboratories?
Caplin Point Laboratories has a dividend yield of 0.16%.
How is the financial performance of Caplin Point Laboratories based on revenue, net income, and EPS?
Caplin Point Laboratories has revenue of INR 2,187.19 crore, net income of INR 641.24 crore, and EPS of INR 84.10.
What is the book value of Caplin Point Laboratories?
Caplin Point Laboratories has a book value of INR 464.74.
What is the debt-to-equity ratio of Caplin Point Laboratories?
Caplin Point Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Caplin Point Laboratories?
Caplin Point Laboratories has a price-to-book ratio of 5.53 and a price-to-sales ratio of 9.00.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.